When did Collegium Pharmaceutical, Inc. report Q4 2024 earnings?

Collegium Pharmaceutical, Inc. (COLL) reported Q4 2024 earnings on February 27, 2025 after market close.

What were Collegium Pharmaceutical, Inc.'s Q4 2024 revenue and EPS?

Collegium Pharmaceutical, Inc. reported revenue of $181.9M and eps of $1.77 for Q4 2024.

Did Collegium Pharmaceutical, Inc. beat estimates in Q4 2024?

Revenue beat the consensus estimate of $179.7M by $2.3M. EPS beat the consensus estimate of $1.54 by $0.23.

Where can I find Collegium Pharmaceutical, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001558370-25-001801) directly on SEC EDGAR. The filing index links above go to sec.gov.

Collegium Pharmaceutical, Inc. COLL Q4 2024 Annual earnings

Reported February 27, 2025 · After market close

Revenue$181.9MBeat by $2.3M

EPS$1.77Beat by $0.23

Revenue estimate$179.7M

EPS estimate$1.54

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$199.6M

EPS estimate$1.68

Financials

Q4 2024

Income statement

See full

Revenue$181.9M+21.5%

Gross profit$98.3M+3.9%

Operating income$38.1M-38.2%

Net income$12.5M-60.8%

EPS (diluted)$0.36-56.1%

Balance sheet

See full

Cash & equivalents$96.6M-59.6%

Total debt$6.8M-4.2%

Total equity$228.8M+17.1%

Total assets$1.7B+45.5%

Cash flow

See full

Operating cash flow$84.6M+15.4%

CapEx$570.0K+248%

Free cash flow$84.1M+14.9%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$923.97M-7.9%

Enterprise value$834.17M+8.1%

P/E13.4×-7.5×

P/S1.5×-0.3×

Profitability

See full

Gross margin59.8%+2.2pp

Operating margin26.9%-2.6pp

Net margin11%+2.5pp

FCF margin33.7%-14.7pp

Returns & leverage

See full

Return on equity32.6%+7.9pp

Debt / equity0×0.0×

Current ratio0.9×-0.2×

Segments

By product

See full

Belbuca$55.2M+12.0%

Jornay PM$29.3M—

Nucynta IR$24.2M-10.9%

Nucynta ER$17.5M-11.0%

Symproic$4.3M-16.4%

By segment

See full

Segment$181.9M+28.4%

Versus estimates

Revenue

Q1 2026$193.5MBeat by $9.0M Q4 2025$205.4MMiss by $913.4K Q3 2025$209.4MBeat by $3.2M Q2 2025$188.0MMiss by $3.3M Q1 2025$177.8MBeat by $4.7M

Q4 2024$181.9MBeat by $2.3M

Diluted EPS

Q1 2026$1.76Beat by $0.24 Q4 2025$2.04Miss by $0.10 Q3 2025$2.25Beat by $0.39 Q2 2025$1.68Beat by $0.06 Q1 2025$1.49Beat by $0.06

Q4 2024$1.77Beat by $0.23

Ask the moment Collegium Pharmaceutical, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Collegium Pharmaceutical, Inc. report Q4 2024 earnings?: Collegium Pharmaceutical, Inc. (COLL) reported Q4 2024 earnings on February 27, 2025 after market close.
What were Collegium Pharmaceutical, Inc.'s Q4 2024 revenue and EPS?: Collegium Pharmaceutical, Inc. reported revenue of $181.9M and eps of $1.77 for Q4 2024.
Did Collegium Pharmaceutical, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $179.7M by $2.3M. EPS beat the consensus estimate of $1.54 by $0.23.
Where can I find Collegium Pharmaceutical, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001558370-25-001801) directly on SEC EDGAR. The filing index links above go to sec.gov.